| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(10 months from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(1 year, 7 months from now) | |
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(3 years from now) | |
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(3 years from now) | |
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(4 years from now) | |
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(7 years from now) | |
Combivent Respimat is owned by Boehringer Ingelheim.
Combivent Respimat contains Albuterol Sulfate; Ipratropium Bromide.
Combivent Respimat has a total of 6 drug patents out of which 0 drug patents have expired.
Combivent Respimat was authorised for market use on 07 October, 2011.
Combivent Respimat is available in spray, metered;inhalation dosage forms.
The generics of Combivent Respimat are possible to be released after 16 October, 2030.
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
COMBIVENT RESPIMAT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic